Nakom (Carbidopa, Levodopa)

Nakom (carbidopa/levodopa) acts on the dopaminergic pathway to alleviate motor deficits in Parkinsonian disorders.

• Parkinson's disease: reduces bradykinesia, rigidity, and tremor, improving daily functioning.
• Parkinsonian syndrome: provides symptomatic relief of motor symptoms in secondary Parkinsonism.
• Levodopa‑responsive Parkinsonism: enhances motor control when symptoms respond to dopaminergic therapy.

• Carbidopa/levodopa combines levodopa, a dopamine precursor that crosses the blood‑brain barrier, with carbidopa, an inhibitor of peripheral aromatic L‑amino‑acid decarboxylase. After oral administration, levodopa is converted to dopamine primarily within the central nervous system, while carbidopa prevents its peripheral conversion, increasing the amount of levodopa reaching the brain and minimizing systemic side effects. The resulting rise in central dopamine restores deficient neurotransmission in the basal ganglia, mitigating the motor manifestations of Parkinsonian disorders.

Common adverse reactions and less frequent serious events have been reported with carbidopa/levodopa therapy.

Common Side Effects

• Nausea: gastrointestinal upset often occurring at treatment initiation.
• Orthostatic hypotension: dizziness or light‑headedness upon standing.
• Dyskinesia: involuntary movements, especially with higher doses.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Psychosis: hallucinations or delusional thinking, particularly in older patients.
• Severe hypotension: marked blood pressure drop leading to syncope.
• Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention.

When prescribing Nakom, clinicians should observe several precautionary measures to optimise safety.

• Blood pressure monitoring: check for orthostatic changes, especially during dose titration.
• Dose adjustment in renal impairment: reduce dose or increase interval in patients with reduced kidney function.
• Psychiatric assessment: evaluate for history of psychosis or depression before initiation.
• Avoid abrupt discontinuation: taper the dose to prevent withdrawal or neuroleptic malignant‑like syndrome.
• Use with caution in the elderly: start at low dose and monitor for dyskinesia and confusion.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Carbidopa/levodopa may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics (e.g., haloperidol): may diminish therapeutic effect.
• COMT inhibitors (e.g., entacapone) without proper dosing adjustments: can cause excessive levodopa levels.
• High‑dose vitamin B6 (pyridoxine): reduces levodopa efficacy unless combined with a decarboxylase inhibitor.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive effect on blood pressure, monitor for hypotension.
• SSRIs or SNRIs: potential for serotonin syndrome, observe for mood changes.
• Iron or calcium supplements: may decrease levodopa absorption, separate administration by at least 2 hours.
• Protein‑rich meals: compete with levodopa absorption, advise timing of doses relative to meals.